Answers are grounded in this paper and cite their sources.
A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Barnes et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: